Trial Profile
Optimization of Treatment With Infliximab in a Medical Setting.
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 10 May 2022
Price :
$35
*
At a glance
- Drugs Infliximab (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
- Acronyms OPTIMIST
- Sponsors Merck Sharp & Dohme Corp.
- 21 Jul 2011 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 21 Jul 2011 Additional primary endpoints added as reported by ClinicalTrials.gov.
- 28 Sep 2010 Actual end date (Mar 2007) added as reported by ClinicalTrials.gov.